or search on
|Title:||A Hepatitis B vaccine booster shot at age 10 could be cost-saving in China: But is it too soon to tell?|
|Authors:||Simms K; Smith MA; Caruana M; Canfell K|
|Categories:||Prevention - Vaccines|
|Journal Title:||International Journal of Infectious Diseases|
|Abstract:||Worldwide, over 240 million people are living with chronic hepatitis B virus (HBV) infection (Ott et al., 2012), and 786,000 individuals die from HBV related deaths, including cirrhosis and liver cancer, each year (MacLachlan et al., 2015, Lozano et al., 2012). The HBV vaccine has been shown to be highly effective, and over one billion doses have been delivered worldwide (World Health Organisation, 2018). The burden of hepatitis B in China is one of the highest in the world, with almost one-third of the world’s hepatitis B cases diagnosed in China. The initial HBV vaccines were licensed in China in 1985 and from 1992 the government actively recommended vaccination of infants, including the first dose being administered within the first 24 hours of birth (Centers for Disease Control and Prevention, 2007, Wang et al., 2016). Since 2002, infant HBV vaccination has been government funded (Cui et al., 2017a). The program has achieved high coverage in infants, with 93.4% receiving three-doses for the 2005 birth cohort; 82.6% received the first dose within the first 24 h of birth (Centers for Disease Control and Prevention, 2007). Survey results have shown declines in hepatitis B virus surface antigen (HBsAg) prevalence in children aged 0–14 years from 10% in 1992 to <1% in 2014 (Cui et al., 2017a), and modelled analyses of HBV vaccination have consistently found that infant HBV vaccination, as well as catch-up vaccination for adolescents, is cost-saving for China (Hutton et al., 2010, Yin et al., 2015).|
|Division:||Cancer Research Division|
|Funding Body:||KC was supported by an NHMRC Fellowship|
|Appears in Collections:||Research Articles|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.